EA201691094A1 - Получение антител для конъюгации из культур клеток cho - Google Patents
Получение антител для конъюгации из культур клеток choInfo
- Publication number
- EA201691094A1 EA201691094A1 EA201691094A EA201691094A EA201691094A1 EA 201691094 A1 EA201691094 A1 EA 201691094A1 EA 201691094 A EA201691094 A EA 201691094A EA 201691094 A EA201691094 A EA 201691094A EA 201691094 A1 EA201691094 A1 EA 201691094A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- conjugation
- purification
- cell cultures
- cho cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/03—Oxidoreductases acting on sulfur groups as donors (1.8) with oxygen as acceptor (1.8.3)
- C12Y108/03002—Thiol oxidase (1.8.3.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение частично основано на наблюдении того, что окислительный фермент из клеток CHO, в частности QSOX1, может переносить, по-видимому, способ жесткой очистки антитела со снижением эффективности последующей конъюгации антитела с лекарственным средством. Перенесет ли окислительный фермент очистку, зависит от того, какие способы очистки используют, что может варьироваться от одного антитела к другому. Зная, что загрязнение окислительным ферментом из клеток CHO является потенциальной проблемой для последующей конъюгации, для любого антитела можно разрабатывать подходящую схему очистки, устраняющую или, по меньшей мере, снижающую окислительные ферменты из CHO до приемлемого уровня.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361908568P | 2013-11-25 | 2013-11-25 | |
PCT/US2014/066889 WO2015077605A1 (en) | 2013-11-25 | 2014-11-21 | Preparing antibodies from cho cell cultures for conjugation |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201691094A1 true EA201691094A1 (ru) | 2016-09-30 |
EA034123B1 EA034123B1 (ru) | 2019-12-30 |
Family
ID=53180202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691094A EA034123B1 (ru) | 2013-11-25 | 2014-11-21 | Получение антител для конъюгации из культур клеток cho |
Country Status (14)
Country | Link |
---|---|
US (2) | US10457976B2 (ru) |
EP (1) | EP3074036B1 (ru) |
JP (2) | JP6529188B2 (ru) |
KR (1) | KR102306493B1 (ru) |
CN (1) | CN105979963B (ru) |
AU (1) | AU2014352824B2 (ru) |
CA (1) | CA2928238C (ru) |
DK (1) | DK3074036T3 (ru) |
EA (1) | EA034123B1 (ru) |
ES (1) | ES2753269T3 (ru) |
IL (1) | IL245190B (ru) |
MX (1) | MX2016006551A (ru) |
SG (2) | SG11201602995VA (ru) |
WO (1) | WO2015077605A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150083689A (ko) * | 2014-01-10 | 2015-07-20 | 삼성전자주식회사 | 항 c-Met 항체 정제 방법 |
EP3252158A4 (en) | 2015-01-26 | 2018-07-18 | Kaneka Corporation | Mutant immunoglobulin kappa chain variable region-binding peptide |
JPWO2016121701A1 (ja) | 2015-01-26 | 2017-11-09 | 株式会社カネカ | 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス |
WO2017109619A1 (en) * | 2015-12-21 | 2017-06-29 | Pfizer Inc. | Purification of antibody drug conjugates using a sodium phosphate gradient |
WO2017195638A1 (ja) * | 2016-05-09 | 2017-11-16 | 株式会社カネカ | 抗体またはκ鎖可変領域含有抗体断片の精製方法 |
WO2018116269A1 (en) * | 2016-12-22 | 2018-06-28 | Lupin Limited | Depth filtration of a protein |
EP3962924A1 (en) * | 2019-05-03 | 2022-03-09 | Genentech, Inc. | Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform |
BR112022002236A2 (pt) | 2019-08-06 | 2022-05-03 | Glaxosmithkline Ip Dev Ltd | Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas |
CA3227515A1 (en) | 2021-08-03 | 2023-02-09 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions and stable isotope labeling peptide mapping method |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
PT871490E (pt) | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | Ligantes de hidrazona ramificada |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
ES2556641T3 (es) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
US8263750B2 (en) * | 2006-03-16 | 2012-09-11 | Amgen Inc. | Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step |
DK2215117T4 (en) * | 2007-10-30 | 2018-04-09 | Genentech Inc | ANTISTO PURIFICATION BY CATION CHANGE CHROMATOGRAPHY |
KR101238061B1 (ko) * | 2009-03-31 | 2013-02-27 | 한화케미칼 주식회사 | Vcam-1에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물 |
CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
US9631028B2 (en) * | 2012-03-07 | 2017-04-25 | Yeda Research And Development Co. Ltd. | Compositions for inhibition of quiescin sulfhydryl oxidase (QSOX1) and uses of same |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
-
2014
- 2014-11-21 DK DK14863650T patent/DK3074036T3/da active
- 2014-11-21 CA CA2928238A patent/CA2928238C/en active Active
- 2014-11-21 ES ES14863650T patent/ES2753269T3/es active Active
- 2014-11-21 MX MX2016006551A patent/MX2016006551A/es unknown
- 2014-11-21 AU AU2014352824A patent/AU2014352824B2/en active Active
- 2014-11-21 JP JP2016533645A patent/JP6529188B2/ja active Active
- 2014-11-21 EA EA201691094A patent/EA034123B1/ru unknown
- 2014-11-21 CN CN201480064191.6A patent/CN105979963B/zh active Active
- 2014-11-21 WO PCT/US2014/066889 patent/WO2015077605A1/en active Application Filing
- 2014-11-21 SG SG11201602995VA patent/SG11201602995VA/en unknown
- 2014-11-21 KR KR1020167016632A patent/KR102306493B1/ko active IP Right Grant
- 2014-11-21 SG SG10201710475WA patent/SG10201710475WA/en unknown
- 2014-11-21 EP EP14863650.9A patent/EP3074036B1/en active Active
- 2014-11-21 US US15/039,179 patent/US10457976B2/en active Active
-
2016
- 2016-04-19 IL IL245190A patent/IL245190B/en active IP Right Grant
-
2018
- 2018-12-26 JP JP2018242033A patent/JP2019048888A/ja active Pending
-
2019
- 2019-09-17 US US16/573,154 patent/US20200063180A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3074036B1 (en) | 2019-09-18 |
EP3074036A4 (en) | 2017-07-26 |
SG10201710475WA (en) | 2018-01-30 |
CN105979963B (zh) | 2020-03-03 |
SG11201602995VA (en) | 2016-05-30 |
AU2014352824B2 (en) | 2019-07-18 |
US20170159099A1 (en) | 2017-06-08 |
KR20160089454A (ko) | 2016-07-27 |
JP2016539130A (ja) | 2016-12-15 |
DK3074036T3 (da) | 2019-11-18 |
IL245190B (en) | 2021-02-28 |
US10457976B2 (en) | 2019-10-29 |
EP3074036A1 (en) | 2016-10-05 |
ES2753269T3 (es) | 2020-04-07 |
WO2015077605A1 (en) | 2015-05-28 |
MX2016006551A (es) | 2016-09-06 |
JP6529188B2 (ja) | 2019-06-12 |
JP2019048888A (ja) | 2019-03-28 |
CN105979963A (zh) | 2016-09-28 |
US20200063180A1 (en) | 2020-02-27 |
CA2928238A1 (en) | 2015-05-28 |
EA034123B1 (ru) | 2019-12-30 |
IL245190A0 (en) | 2016-06-30 |
KR102306493B1 (ko) | 2021-09-28 |
CA2928238C (en) | 2021-08-17 |
AU2014352824A1 (en) | 2016-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691094A1 (ru) | Получение антител для конъюгации из культур клеток cho | |
CY1121217T1 (el) | Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
EA201791633A1 (ru) | Способ точной модификации растения посредством транзиентной экспрессии гена | |
EA202092987A3 (ru) | Липид, содержащий докозапентаеновую кислоту | |
UY34227A (es) | Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo | |
TR201904270T4 (tr) | Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller. | |
UY34559A (es) | Inhibidores de bromodominios | |
UY34342A (es) | ?derivados de pirrolopirimidina y purina?. | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
ECSP13013084A (es) | Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b | |
UY34824A (es) | Nucleósidos de espirooxetano de uracilo | |
EA201490886A1 (ru) | Переработка биомассы | |
UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
UY32501A (es) | Anticuerpo antagonista específico para el heterodímero alfa4-beta7 | |
EA201490885A1 (ru) | Переработка материалов биомассы | |
CL2013002068A1 (es) | Linea celular de ratón con genes inactivados nav1.7 global viable; metodo para generar ratón con dichos genes inactivados; hibridoma. | |
GB2548740A (en) | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | |
TW201612308A (en) | Collector architecture layout design | |
EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
EA201690718A1 (ru) | Способ обработки целлюлозосодержащей биомассы | |
BR112016009753A2 (pt) | método de cultura de células. | |
AR093330A1 (es) | Metodo para la remocion de adn | |
BR112014026440A2 (pt) | assays, methods and apparatus for assessing rna disruption | |
EA201890710A1 (ru) | Способ очистки гидролизата биомассы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC4A | Change in name of a patent proprietor in a eurasian patent |